Original Article: bit.ly/1wkBIR9
A survey of users of Truvada (tenofovir/emtricitabine) as pre-exposure prophylaxis (PrEP) at a San Francisco hospital found that 45 percent reported using condoms less frequently since starting PrEP, the San Francisco Business Times reports. Clinicians at the Kaiser Permanente Medical Center in San Francisco surveyed 90 of the approximately 500 people who have started PrEP at the hospital. C. Bradley Hare, MD, the director of HIV care and prevention services at the hospital, presented findings from the survey at a World AIDS Day community forum in San Francisco.
Forty-five percent of the surveyed PrEP users reported using condoms less frequently since starting Truvada, while 5 percent reported using them more, and 50 percent reported no change. No one reported an increase in sexual partners. There have been no new cases of HIV among all 500 PrEP users at the hospital.
Speaking with POZ, Hare characterizes the survey’s findings as “extremely preliminary. I think it’s too preliminary to draw any widespread conclusions.”
Hare stresses that these findings did not come from an actual research study. Because Kaiser did not develop a comparison, or control, group, it is impossible to deduce whether any decrease in condom use might have occurred without the addition of PrEP.
Additionally, Hare underlines the fact that the survey was not designed to determine the degree to which PrEP users are using condoms less frequently.
Full text of article available at link below: bit.ly/1wkBIR9